RASNA THERAPEUTICS, INC. (OTCMKTS:RASP) Files An 8-K Entry into a Material Definitive Agreement
Item 1.01 Entry into a Material Definitive Agreement.
Item 3.02Unregistered Sale of Equity Securities
On December 20, 2016, Rasna Therapeutics,Inc. (the
Company) entered into a securities purchase agreement with
certain accredited investors, as defined in RegulationD
promulgated under the Securities Act of 1933, as amended (the
Securities Act), to which the Company sold the investors
an aggregate of 3,366,667 shares of common stock common stock,
par value $0.0001 per share for aggregate gross proceeds of
$2,020,000.
The securities sold in the private placement were not registered
under the Securities Act, or the securities laws of any state,
and were offered and sold in reliance on the exemption from
registration afforded by Section4(2)and Regulation D (Rule506)
under the Securities Act and corresponding provisions of state
securities laws, which exempt transactions by an issuer not
involving any public offering. Each investor is an accredited
investor as such term is defined in Regulation D promulgated
under the Securities Act. This current report shall not
constitute an offer to sell or the solicitation of an offer to
buy, nor shall such securities be offered or sold in the United
States absent registration or an applicable exemption from the
registration requirements and certificates evidencing such shares
contain a legend stating the same.
The foregoing information is a summary of the securities purchase
agreement involved in the transaction described above, is not
complete, and is qualified in its entirety by reference to the
full text of such agreement, a copy of which is attached as an
exhibit to this Current Report on Form8-K.
Item 8.01 Other Items.
On December 27, 2016, the Company issued a press release
announcing that it has closed a private placement to accredited
investors. A copy of the Companys press release is furnished as
Exhibit99.1 to this Current Report on Form8-K.
| Item9.01 | Financial Statements and Exhibits |
| (d) | Exhibits. |
The exhibits listed in the following Exhibit Index are filed as
part of this Current Report on Form 8-K.
| Exhibit No . | Description | |
| 10.1 | Form of Securities Purchase Agreement | |
| 99.1 | Press release dated December 27, 2016. |
About RASNA THERAPEUTICS, INC. (OTCMKTS:RASP)
Rasna Therapeutics, Inc., formerly Active With Me Inc., creates online resources that offer travelers information on activity-based travel. The Company’s Website focuses on offering third-party content and information to visitors in their activity of choice. The Company’s Website also focuses on offering links to clubs and organizations. The Company is in development-stage. Rasna DE is the subsidiary of the Company. Rasna DE is engaged in modulating the molecular targets nucleophosmin gene (NPM1) and lysine (K)-specific demethylase 1A (LSD1), which are implicated in the disease progression of leukemia and lymphoma. The Company focuses on performing preclinical research on NPM1 and LSD1. As of June 30, 2016, the Company had not generated any revenues. RASNA THERAPEUTICS, INC. (OTCMKTS:RASP) Recent Trading Information
RASNA THERAPEUTICS, INC. (OTCMKTS:RASP) closed its last trading session 00.00 at 1.85 with shares trading hands.
